MENU

PALI Stock Palisade Bio (PALI, $1.9) Stochastic Oscillator left the oversold zone on December 17, 2024

A.I.dvisor
at Tickeron.com
Loading...
PALI - Palisade Bio
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $1.9
Daily change: +$0.06 (+3.26%)
Daily volume: 667.6K
Capitalization: $3.3M
Industry: Biotechnology
This is a signal that PALI's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 72 similar cases where PALI's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

PALI in upward trend: price may ascend as a result of having broken its lower Bollinger Band on December 10, 2024

PALI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 48 cases where PALI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PALI's RSI Indicator exited the oversold zone, of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for PALI just turned positive on December 16, 2024. Looking at past instances where PALI's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PALI advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 29, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on PALI as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PALI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PALI entered a downward trend on December 11, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.462) is normal, around the industry mean (14.678). P/E Ratio (0.018) is within average values for comparable stocks, (87.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.782). PALI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (11.779) is also within normal values, averaging (260.407).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
7750 El Camino Real
Phone
+1 858 704-4900
Employees
9
Web
https://www.palisadebio.com